Intracellular antibodies and challenges facing their use as therapeutic agents

被引:75
|
作者
Lobato, MN [1 ]
Rabbitts, TH [1 ]
机构
[1] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
关键词
D O I
10.1016/S1471-4914(03)00163-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A key feature of antibodies is their ability to bind antigens with high specificity and affinity. This has led to the concept of intracellular antibodies (intrabodies), designed to mimic antibody-antigen binding, but inside cells. Antibody fragments comprising the antigen-binding variable domains are convenient formats for intrabodies, potentially allowing for intracellular functionality. Intrabodies are promising tools, capable of interfering with a wide range of molecular targets in various intracellular compartments. However, many significant challenges remain to be overcome before intrabodies can be useful therapeutic agents. Although major progress has been made in the design and selection of intrabodies, new developments and advances are needed to allow their efficient delivery and expression for treatment of human diseases.
引用
收藏
页码:390 / 396
页数:7
相关论文
共 50 条
  • [31] Challenges in the Discovery of Novel Therapeutic Agents in Cancer
    Nagaraju, Ganji Purnachandra
    Kamal, Mohammad Amjad
    CURRENT DRUG METABOLISM, 2019, 20 (12) : 931 - 932
  • [32] Antimicrobial peptides as therapeutic agents: opportunities and challenges
    Mahlapuu, Margit
    Bjorn, Camilla
    Ekblom, Jonas
    CRITICAL REVIEWS IN BIOTECHNOLOGY, 2020, 40 (07) : 978 - 992
  • [33] Being the bearer of bad news: Challenges facing downsizing agents in organizations
    Clair, Judith A.
    Dufresne, Ronald
    Jackson, Nicole
    Ladge, Jamie
    ORGANIZATIONAL DYNAMICS, 2006, 35 (02) : 131 - 144
  • [34] Intracellular antibodies and cancer: New technologies offer therapeutic opportunities
    Perez-Martinez, David
    Tanaka, Tomoyuki
    Rabbitts, Terence H.
    BIOESSAYS, 2010, 32 (07) : 589 - 598
  • [35] THE THERAPEUTIC USE OF MONOCLONAL-ANTIBODIES
    CHATENOUD, L
    BACH, JF
    CURRENT OPINION IN IMMUNOLOGY, 1988, 1 (02) : 257 - 260
  • [36] Patentability of antibodies for therapeutic use in Europe
    Germinario, Claudio
    Bertoli, Sara
    Rampinelli, Patrizia
    Cini, Maurizio
    NATURE BIOTECHNOLOGY, 2018, 36 (05) : 402 - 406
  • [37] Proapoptotic antibodies as new therapeutic agents for tumor treatment
    Schenck, M.
    Boergermann, C.
    vom Dorp, F.
    Groneberg, M.
    Busch, Y.
    Carpinteiro, A.
    Wilker, B.
    Keitsch, S.
    Moyrer, S.
    Schmid, K. W.
    Stuschke, M.
    Ruebben, H.
    Gulbins, E.
    UROLOGE, 2007, 46 (09): : 1262 - 1265
  • [38] TARGETING OF ANTICANCER THERAPEUTIC AGENTS BY MONOCLONAL-ANTIBODIES
    EMBLETON, MJ
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1986, 14 (02) : 393 - 395
  • [39] Monoclonal antibodies as effective therapeutic agents for solid tumors
    Hinoda, Y
    Sasaki, S
    Ishida, T
    Imai, K
    CANCER SCIENCE, 2004, 95 (08) : 621 - 625
  • [40] Monoclonal antibodies used as prophylactic, therapeutic and diagnostic agents
    Chakhtoura, Marita
    Abdelnoor, Alexander M.
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2010, 32 (04) : 533 - 542